Will My GP Give Me Mounjaro on the NHS?

What NICE said, and why that does not always mean your GP can prescribe today

NICE published its recommendation for tirzepatide in December 2024, a decision backed by evidence from the SURMOUNT-1 trial, which found average body-weight reductions of around 20–21% at the highest dose over 72 weeks, figures that caught the attention of clinicians and patients alike. You can read NICE's appraisal of tirzepatide (TA1026) in full if you want to see exactly how the committee weighed that data.

A NICE recommendation, though, is not the same as a GP prescription pad. NHS England chose to implement access in careful stages rather than open the gates immediately, partly because of supply and partly because demand for GLP-1 medicines is enormous. So a positive NICE recommendation creates an entitlement, not an instant appointment.

From April 2026, GP practices could begin prescribing tirzepatide under the new QOF contract, but participation is optional. Some practices signed up; others have not yet done so, or are waiting for local infrastructure such as dietitian support to be in place. If your GP says they cannot prescribe Mounjaro, it may be a practice-level decision rather than a clinical one about you personally, and whether your doctor will give you Mounjaro for weight loss explores exactly that distinction in more detail. Worth asking, calmly, whether their practice has joined the scheme.

Who a GP can currently prescribe Mounjaro for on the NHS

NHS England's phased rollout determines who qualifies, and the criteria are specific. In the first cohort, active from June 2025, tirzepatide is available to adults with a BMI of 40 or above who also have four or more qualifying conditions from a defined list: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. That is a high bar, most people with obesity who contact their GP will not meet all four.

A second cohort opened in June 2026, covering adults with a BMI of 35–39.9 plus four or more of those same conditions. A third phase, targeting adults with a BMI of 40 or more and three conditions, is expected around March 2027. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the BMI thresholds are reduced by 2.5 kg/m² throughout. You can use the NHS BMI calculator to check where you currently sit, though a number on a screen does not replace clinical assessment.

Even if you meet the numbers, your GP cannot prescribe without the wraparound support structure (a reduced-calorie programme, activity guidance, and ongoing monitoring) being available at your practice or via referral. Not every area has that in place yet. How GP prescribing for Mounjaro actually works covers what to expect from that appointment in more detail.

What your GP is likely to say if you do not yet qualify on the NHS

This is where many conversations with a GP quietly stall. Your BMI might be 34, or you might have only one or two weight-related conditions rather than four. In those cases, a GP following NHS guidance cannot prescribe Mounjaro yet, not because tirzepatide would not help you, but because the rollout has not reached that cohort. Waiting lists for specialist weight management services (through which NHS semaglutide (Wegovy) is also available) are commonly long.

Some GPs will discuss a private prescription in this situation; others will not, or will simply refer you elsewhere. Private prescriptions are not written at the NHS rate and are not subsidised, so cost is a real consideration. For a broader picture of tirzepatide as a treatment, the tirzepatide overview walks through the clinical evidence, the dosing schedule, and the eligibility criteria in one place. And if you want a sense of whether treatment is likely to be suitable for your own situation, whether Mounjaro is likely to work for you looks honestly at the factors that influence outcomes.

Private routes: what they are and what they are not

A regulated private online pharmacy (one you can verify on the GPhC register before you share any health information) can offer Mounjaro via a private prescription following clinical assessment. That assessment is a real clinical review, not a formality; a GPhC-registered prescriber reads your answers and makes a professional decision about suitability. No guarantee of approval, no algorithm.

Private treatment does not replace your GP, and it does not come cheap, particularly since Eli Lilly adjusted list prices in autumn 2025. The Eli Lilly Mounjaro price increase page explains what changed and why private costs look the way they do now. What a legitimate service should always include is a real prescription from a named clinician, a verifiable pharmacy, genuine supply-chain medicine, and clinical support if questions arise, including clear guidance on how to give Mounjaro correctly once your treatment begins. The weight-loss treatments overview sets out the full landscape of what is licensed and available in the UK if you are still deciding which route suits you.

If your GP appointment left you without a clear path forward, a private consultation with a prescriber is a reasonable next step. At nume, a GPhC-registered Independent Prescriber reviews every consultation personally, and if treatment is clinically appropriate, medicines are dispatched the same day. Start your free consultation to see whether you are eligible.